Clinical trials: in Mali
Malaria
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
Malaria caused by Plasmodium falciparum continues to be a global problem with devastating consequences. A greater understanding of the immunologic and parasitologic factors associated with infection and disease is badly needed…
- Trial name
- NCT01168271
- Where
- 2 sites in Mali
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Vector Transmission
Attractive Targeted Sugar Bait Trial in Mali
Globally, the female mosquitoes to be effective at transmitting malaria parasites, must have a number of characteristics including: abundance, longevity (individual mosquitoes must survive long enough after feeding on infected…
- Trial name
- NCT04149119
- Testing
- Attractive Target Sugar Baits (ATSB)
- Where
- Mali
- Volunteers
- 6,068 people, healthy volunteers welcome
- Sponsor
- University Clinical Research Center, Mali
Malaria
L9LS in Women of Childbearing Potential in Mali
Safety and Efficacy of L9LS, a Human Monoclonal Antibody Against Plasmodium falciparum, in a Randomized, Double-Blind, Placebo-Controlled Trial of Women of Childbearing Potential (WOCBP) in Mali
- Trial name
- NCT07060508
- Testing
- Single dose of 1800 mg L9LS SC
- Where
- 3 sites in Mali
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
Variants of SARS-CoV-2 Causing COVID-19 in Africa
The main objective of this research is to identify and characterize the different molecular variants of SARS-CoV-2, emerging and / or circulating in several countries of Sub-Saharan Africa (Burkina Faso, Côte d'Ivoire, Gabon…
- Trial name
- South-Spike (NCT05311891)
- Testing
- RT PCR
- Where
- 6 sites in Burkina Faso, Chad and 4 more
- Volunteers
- 12,600 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Malaria
Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates
Background: Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and treated right away.
- Trial name
- NCT02471378
- Where
- Mali
- Volunteers
- 7,476 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
L9LS MAb in Malian Infants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of L9LS in infants in Mali and to evaluate the impact of L9LS on subsequent R21/Matrix-MTM vaccine immunogenicity.
- Trial name
- NCT06461026
- Testing
- L9LS, R21/Matrix-MTM
- Where
- 3 sites in Mali
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.
This is a Phase 1b, single-cente, randomized, double-blind, placebo-controlled proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and mosquitocidal activity of single oral doses of lotilaner in healthy…
- Trial name
- NCT07758985
- Testing
- Cohort 1 low dose lotilaner with a high-fat meal, Cohort 2 high dose lotilaner in fasted state, Cohort 3 high dose lotilaner with a high-fat meal
- Where
- Mali
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Stillbirths and Infant Mortality
Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali
The double blind randomized controlled trial will assess the efficacy of oral azithromycin administered to pregnant women and/or infants during routine care in preventing stillbirths and mortality through 6-12 months of age in…
- Trial name
- SANTE (NCT03909737)
- Testing
- Azithromycin to pregnant women, Azithromycin to infants, No intervention to pregnant women
- Where
- Mali
- Volunteers
- 99,700 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Malaria (Plasmodium Falciparum)
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10^5 PfSPZ or placebo in healthy…
- Trial name
- NCT07675785
- Testing
- PfSPZ-LARC2 Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Prevention of Malaria Transmission and Clinical Malaria
Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults
This is a Phase 2, randomized, double-blind, controlled study designed to evaluate the safety, tolerability, immunogenicity, vaccine efficacy, and functional activity of Pfs230D1-CRM197 conjugate vaccine with R21 nanoparticle…
- Trial name
- NCT07147400
- Testing
- 10µg of R21 with 50µg Matrix-M1, 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation, RABIVAX-S
- Where
- Mali
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Trivalent Salmonella Conjugate Vaccine (TSCV)
Trivalent Salmonella Conjugate Vaccine (TSCV)
This is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV).
- Trial name
- NCT05784701
- Testing
- TSCV (Full-strength), TSCV (Half-strength), Typbar-TCV
- Where
- Mali
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Meningoccocal Disease
Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.
- Trial name
- PERS-ACYWX-03 (NCT07379151)
- Where
- 2 sites in Mali, The Gambia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Measles Infection
Investigation of Immune Amnesia Following Measles Infection in Select African Regions
The goal of this observational study is to investigate the effects of measles virus (MeV) infection on pre-existing immunity, vaccine response, and susceptibility to subsequent illness in children aged 1-15 either with or without…
- Trial name
- NCT06153979
- Testing
- Verorab
- Where
- 2 sites in Guinea, Mali
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)
This demonstration project will assess the acceptability and feasibility of pre-exposure prophylaxis (PrEP) for men who have sex with men (MSM) as part of a comprehensive HIV prevention package in community-based clinics in West…
- Trial name
- CohMSM-PrEP (NCT03459157)
- Testing
- HIV prevention package including PrEP
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 649 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Atopic Disease
Microbiome and Atopy in Mali
This study is about allergic diseases in people living in Mali. Allergic diseases can cause health problems like asthma or skin rashes.
- Trial name
- NCT07051902
- Where
- 2 sites in Mali
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infection
Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa
The objective of the study is to evaluate the feasibility and interest of a HIV quarterly preventive global care for men who have sex with men (MSM) in sub-Saharan Africa to help reducing HIV incidence in this key population…
- Trial name
- CohMSM (NCT02626286)
- Testing
- HIV quarterly global care
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 885 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Malaria
L9LS-R21 Interaction
This is a randomized, double-blind, placebo-controlled trial in 2 parts evaluating the effect of 1-time administration of the monoclonal antibody (MAb) L9LS to healthy Malian participants on the immunogenicity of subsequent…
- Trial name
- NCT07208760
- Testing
- Single dose of 1800 mg L9LS SC (12mL), Single dose of 225 mg L9LS SC (1.5mL)
- Where
- Mali
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines
This is a Phase Ib trial conducted in Bougouni, Mali to evaluate the safety and immunogenicity of R21/Matrix-M in a single and two vial presentation, with different immunisation schedules, and when co-administered with EPI…
- Trial name
- NCT05155579
- Testing
- R21/Matrix-M - single vial formulation, R21/Matrix-M - two vial formulation, Licensed vaccine - Measles-rubella
- Where
- 2 sites in Mali, United Kingdom
- Volunteers
- 594 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Meningitis
Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine
Infants aged 9 months will be randomized to receive a meningococcal vaccine at 9 months or 15 months. Infants randomized to the 9-month age group will be further randomized in a 2:1 ratio to receive a single dose of the…
- Trial name
- NCT05093829
- Testing
- NmCV-5, MenACWY-TT
- Where
- Mali
- Volunteers
- 1,325 people, healthy volunteers welcome
- Sponsor
- Emory University
Malaria, Pregnancy Related
Pregnancy Registry in Mali
This registry will assess pregnancy outcomes through demographic surveillance and prospective data collection at a health facility in Kalifabougou, Mali.
- Trial name
- NCT06468319
- Where
- Mali
- Volunteers
- 9,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)